34 results on '"Moretto N"'
Search Results
2. Engaging the public in healthcare decision-making: results from a Citizens’ Jury on emergency care services
- Author
-
Scuffham, P A, primary, Moretto, N, additional, Krinks, R, additional, Burton, P, additional, Whitty, J A, additional, Wilson, A, additional, Fitzgerald, G, additional, Littlejohns, P, additional, and Kendall, E, additional
- Published
- 2016
- Full Text
- View/download PDF
3. An entropy based multithresholdingmethod for semi-automatic segmentation of liver tumors
- Author
-
Choudhary, A., Moretto, N., PIZZORNI FERRARESE, Francesca, and Zamboni, G. A.
- Subjects
Segmentation ,Liver tumor ,Medical Imaging - Published
- 2008
4. ETUDE DE LA QUALITE DE L'AIR SUR UNE POPULATION DE PERSONNES TRAVAILLANT DANS DES BUREAUX (Indoor air quality in offices: Subjective evaluations and symptoms)
- Author
-
Maina, Giovanni, Sonnino, A, Cerina, G, Moretto, N, and Rubino, Gf
- Subjects
indoor air pollution ,psychological aspect ,adult ,article ,humidity ,work environment ,air quality ,female ,male ,office worker ,controlled study ,human ,normal human - Published
- 1994
5. Acrolein Contained in Cigarette Smoke Elicits Vascular Endothelial Growth Factor (VEGF) Release in Normal Human Lung Fibroblasts.
- Author
-
Facchinetti, F, primary, Moretto, N, additional, Volpi, G, additional, Civelli, M, additional, and Patacchini, R, additional
- Published
- 2009
- Full Text
- View/download PDF
6. Bayesian surface reconstruction.
- Author
-
Moretto, N. and Frezza, R.
- Published
- 2004
- Full Text
- View/download PDF
7. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid<INF>1</INF><INF>-</INF><INF>42</INF> Secretion
- Author
-
Peretto, I., Radaelli, S., Parini, C., Zandi, M., Raveglia, L. F., Dondio, G., Fontanella, L., Misiano, P., Bigogno, C., Rizzi, A., Riccardi, B., Biscaioli, M., Marchetti, S., Puccini, P., Catinella, S., Rondelli, I., Cenacchi, V., Bolzoni, P. T., Caruso, P., Villetti, G., Facchinetti, F., Giudice, E. Del, Moretto, N., and Imbimbo, B. P.
- Abstract
Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit β-amyloid
1 - 42 (Aβ42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing Aβ42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on Aβ42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Aβ42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.- Published
- 2005
8. Volumetric reconstruction by random sampling.
- Author
-
Moretto, N., Cugola, N., and Frezza, R.
- Published
- 2003
- Full Text
- View/download PDF
9. CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.
- Author
-
Martucci C, Allen AD, Moretto N, Bagnacani V, Fioni A, Patacchini R, Civelli M, Villetti G, and Facchinetti F
- Abstract
Inhibition of p38 mitogen-activated protein kinase (MAPKs) is a potential therapeutic approach for the treatment of acute and chronic pulmonary inflammatory conditions. Here, we report the in vitro and in vivo characterization of the anti-inflammatory effects of CHF6297, a novel potent and selective p38α inhibitor designed for inhalation delivery as a dry powder formulation. CHF6297 has been proven to inhibit p38α enzymatic activity with sub-nanomolar potency (IC
50 = 0.14 ± 0.06 nM), with >1,000-fold selectivity against p38γ and p38δ. In human peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharides (LPS), as well as in human bronchial epithelial cells (BEAS2B) stimulated with TNF-α or cigarette smoke extract (CSE), CHF6297 inhibited interleukin (IL)-8 release with low nanomolar potency. CHF6297 administered to rats by using a nose-only inhalation device as a micronized dry powder formulation blended with lactose dose-dependently inhibited the LPS-induced neutrophil influx in the bronchoalveolar lavage fluid (BALF). CHF6297 administered intratracheally to rats dose-dependently counteracted the IL-1β (0.3 mg/kg)-induced neutrophil influx (ED50 = 0.22 mg/kg) and increase in IL-6 levels (ED50 = 0.82 mg/kg) in the BALF. In mice exposed to tobacco smoke (TS), CHF6297, administered intranasally (i.n.) for 4 days at 0.03 or 0.3 mg/kg, dose-dependently inhibited the corticosteroid-resistant TS-induced neutrophil influx in the BALF. In a murine house dust mite (HDM) model of asthma exacerbated by influenza virus A (IAV) (H3N3), CHF6297 (0.1 mg/kg, i.n.) significantly decreased airway neutrophilia compared to vehicle-treated IAV/HDM-challenged mice. When CHF6297, at a dose ineffective per se (0.03 mg/kg), was added to budesonide, it augmented the anti-inflammatory effects of the steroid. Overall, CHF6297 effectively counteracted lung inflammation in experimental models where corticosteroids exhibit limited anti-inflammatory activity, suggesting a potential for the treatment of acute exacerbations associated with chronic obstructive pulmonary disease (COPD) and asthma, acute lung injury (ALI), and viral-induced hyperinflammation., Competing Interests: Authors CM, AA, NM, VM, AF, RP, MC, GV, and FF were employed by Chiesi Farmaceutici S.p.A. The authors declare that this study received funding from Chiesi Farmaceutici S.p.A. The funder was not involved in the study design, collection, analysis, interpretation of data and the writing of this article but only in the final check and approval for submission., (Copyright © 2024 Martucci, Allen, Moretto, Bagnacani, Fioni, Patacchini, Civelli, Villetti and Facchinetti.)- Published
- 2024
- Full Text
- View/download PDF
10. Design, Synthesis, and Biological Characterization of Inhaled p38α/β MAPK Inhibitors for the Treatment of Lung Inflammatory Diseases.
- Author
-
Armani E, Capaldi C, Bagnacani V, Saccani F, Aquino G, Puccini P, Facchinetti F, Martucci C, Moretto N, Villetti G, Patacchini R, Civelli M, Hurley C, Jennings A, Alcaraz L, Bloomfield D, Briggs M, Daly S, Panchal T, Russell V, Wicks S, Finch H, Fitzgerald M, Fox C, and Delcanale M
- Subjects
- Animals, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Drug Design, Phosphorylation, Rats, Mitogen-Activated Protein Kinase 14 antagonists & inhibitors, Pneumonia drug therapy, Pneumonia enzymology, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors pharmacology, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors
- Abstract
The identification of novel inhaled p38α/β mitogen-activated protein kinases (MAPK) (MAPK14/11) inhibitors suitable for the treatment of pulmonary inflammatory conditions has been described. A rational drug design approach started from the identification of a novel tetrahydronaphthalene series, characterized by nanomolar inhibition of p38α with selectivity over p38γ and p38δ isoforms. SAR optimization of 1c is outlined, where improvements in potency against p38α and ligand-enzyme dissociation kinetics led to several compounds showing pronounced anti-inflammatory effects in vitro (inhibition of TNFα release). Targeting of the defined physicochemical properties allowed the identification of compounds 3h , 4e , and 4f , which showed, upon intratracheal instillation, low plasma levels, prolonged lung retention, and anti-inflammatory effects in a rat acute model of a bacterial endotoxin-induced pulmonary inflammation. Compound 4e , in particular, displayed remarkable efficacy and duration of action and was selected for progression in disease models of asthma and chronic obstructive pulmonary disease (COPD).
- Published
- 2022
- Full Text
- View/download PDF
11. Allied health primary contact services: results of a 2-year follow-up study of clinical effectiveness, safety, wait times and impact on medical specialist out-patient waitlists.
- Author
-
Stute M, Moretto N, Waters R, Raymer M, Sam S, Bhagwat M, Banks M, Comans T, and Buttrum P
- Subjects
- Adult, Follow-Up Studies, Humans, Prospective Studies, Queensland, Treatment Outcome, Outpatients, Waiting Lists
- Abstract
Objective Long specialist out-patient waitlists are common in public health facilities, but not all patients require consultation with a medical specialist. Studies of single allied health primary contact services have shown they provide timely, appropriate care and reduce demand on medical specialist out-patient waitlists. This study evaluated the collective benefits across multiple allied health primary contact services and models to determine their clinical effectiveness, safety, timeliness of care and impact on medical specialist out-patient waitlists. Method Using a prospective observational study design, data were collected and analysed for patients attending 47 allied health primary contact services in Queensland public hospitals over a 2-year period. Outcomes reported are global status, adverse events, wait times and impact on medical specialist out-patient waitlists. Results In all, 10634 patients were managed in and discharged from the allied health services. Most adult patients (80%) who attended at least two consultations reported an improvement in health status. No adverse events were attributed to the model of care. Approximately 68%, 44% and 90% of urgent, semi-urgent and non-urgent out-patients respectively were seen within clinically recommended time frames. Between 35% and 89% of patients were removed from out-patient waitlists without medical specialist consultation across the service models. Conclusions Allied health primary contact services provide safe, effective and timely care. The impact on medical specialist out-patient waitlists varied depending on service model and pathway characteristics. What is known about this topic? Most studies of allied health primary contact services have focused on the management of patients on orthopaedic specialist out-patient waitlists by a physiotherapist. These studies of either individual services or groups of services with the same model cite benefits, including reduced waiting times, high levels of patient and referrer satisfaction, improved conversion to surgery, cost-effectiveness and more effective utilisation of medical specialists. What does this paper add? This paper highlights that, collectively, allied health primary contact services are safe, effective and provide timely care. The proportion of patients independently managed and removed from various medical specialist out-patient waitlists and the services involved are reported, demonstrating the variety of service models. This study reports outcomes for primary contact services for which there is a dearth of published literature, including dietician services for patients on gastroenterology waitlists, speech pathology and audiology services for patients on ear, nose and throat waitlists, occupational therapy hand services for patients on orthopaedic waitlists and physiotherapy led pelvic-health services for patients on gynaecology waitlists. Possibilities for efficiency gains are identified and discussed. What are the implications for practitioners? Health service managers should consider allied health primary contact services as a viable option to increase specialist out-patient capacity. Service model characteristics that maximise impact on medical specialist out-patient waitlist management are highlighted to inform resource allocation.
- Published
- 2021
- Full Text
- View/download PDF
12. Translating research into practice: outcomes from the Healthy Living after Cancer partnership project.
- Author
-
Eakin EG, Reeves MM, Goode AD, Winkler EAH, Vardy JL, Boyle F, Haas MR, Hiller JE, Mishra GD, Jefford M, Koczwara B, Saunders CM, Chapman K, Hing L, Boltong AG, Lane K, Baldwin P, Millar L, McKiernan S, Demark-Wahnefried W, Courneya KS, Job J, Reid N, Robson E, Moretto N, Gordon L, and Hayes SC
- Subjects
- Female, Humans, Male, Middle Aged, Treatment Outcome, Healthy Lifestyle physiology, Neoplasms rehabilitation
- Abstract
Background: Healthy Living after Cancer (HLaC) was a national dissemination and implementation study of an evidence-based lifestyle intervention for cancer survivors. The program was imbedded into existing telephone cancer information and support services delivered by Australian state-based Cancer Councils (CC). We report here the reach, effectiveness, adoption, implementation, and maintenance of the program., Methods: In this phase IV study (single-group, pre-post design) participants - survivors of any type of cancer, following treatment with curative intent - received up to 12 nurse/allied health professional-led telephone health coaching calls over 6 months. Intervention delivery was grounded in motivational interviewing, with emphasis on evidence-based behaviour change strategies. Using the RE-AIM evaluation framework, primary outcomes were reach, indicators of program adoption, implementation, costs and maintenance. Secondary (effectiveness) outcomes were participant-reported anthropometric, behavioural and psychosocial variables including: weight; physical activity; dietary intake; quality-of-life; treatment side-effects; distress; and fear of cancer recurrence and participant satisfaction. Changes were evaluated using linear mixed models, including terms for timepoint (0/6 months), strata (Cancer Council), and timepoint x strata., Results: Four of 5 CCs approached participated in the study. In total, 1183 cancer survivors were referred (mostly via calls to the Cancer Council telephone information service). Of these, 90.4% were eligible and 88.7% (n = 791) of those eligible consented to participate. Retention rate was 63.4%. Participants were mostly female (88%), aged 57 years and were overweight (BMI = 28.8 ± 6.5 kg/m2). Improvements in all participant-reported outcomes (standardised effect sizes of 0.1 to 0.6) were observed (p < 0.001). The program delivery costs were on average AU$427 (US$296) per referred cancer survivor., Conclusions: This telephone-delivered lifestyle intervention, which was feasibly implemented by Cancer Councils, led to meaningful and statistically significant improvements in cancer survivors' health and quality-of-life at a relatively low cost., Trial Registration: Australian and New Zealand Clinical Trials Registry (ANZCTR) - ACTRN12615000882527 (registered on 24/08/2015).
- Published
- 2020
- Full Text
- View/download PDF
13. Use of Reimbursed Psychology Videoconference Services in Australia: An Investigation Using Administrative Data.
- Author
-
Wilson A, Moretto N, Langbecker D, and Snoswell CL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Australia, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Reimbursement Mechanisms trends, Retrospective Studies, Social Work, Psychiatric economics, Social Work, Psychiatric trends, Telemedicine methods, Videoconferencing economics, Videoconferencing trends, Reimbursement Mechanisms standards, Social Work, Psychiatric methods, Telemedicine economics, Videoconferencing instrumentation
- Abstract
Background: In November 2017, the Australian government approved reimbursement for psychology consultations conducted by videoconference under the Better Access initiative to address inequitable access of mental health services across regions in Australia., Objective: This project uses publically available activity data from the Medicare Benefits Scheme to quantify the uptake of videoconference for psychology resulting from the initiative change., Methods: Data were extracted from the Medicare Benefits Schedule item reports using the item codes for standard consultations and the new item codes for videoconference consultations. Activity data from 2 years before and the first year of the change to the Better Access initiative were compared to examine the uptake of videoconference for psychology. Data were stratified by allied health profession, sex, age and state jurisdiction., Results: In the 1-year period after the introduction of reimbursed videoconference consultations, approximately 5.7 million in-person consultations and 4141 videoconference consultations were funded by Medicare in Australia. Videoconference consultations comprised 0.07% of the total consultations performed in that 1-year period and showed an increased trajectory. The results can guide future research into evaluating the clinical outcomes of patients via both in-person and videoconference delivery modes., Conclusions: Videoconference mental health services were used in the first year that they were available, although they only accounted for a small percentage of all mental health consultations provided by allied health professionals. This finding lays the foundation for future work which could examine the effectiveness of the scheme in reducing inequity and investigating the economic benefits of the expanded initiative to the government and society., (Copyright © 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
14. A uniform data set for determining outcomes in allied health primary contact services in Australia.
- Author
-
Moretto N, Stute M, Sam S, Bhagwat M, Raymer M, Buttrum P, Banks M, and Comans TA
- Abstract
The project aim was to develop and implement a set of metrics to capture and demonstrate the performance of newly established allied health primary contact services. Selection of the metrics and performance indicators was guided by an existing state-wide data collection system and from a review of the published literature. The metrics were refined after consultation with a working group of health service managers and clinicians. The data collection and reporting framework were developed for use in allied health primary contact services and implemented at public health facilities in Queensland, Australia. The set of metrics consists of 18 process and outcome measures. Patient-reported metrics include the global rating of change scale and patient satisfaction. Service metrics include wait times; referral source; triage category; diagnosis; occasions of service; referrals and investigations initiated; effects; care duration; discharge status; waitlist reinstatement reasons; treatment non-completion reasons; and expedited care. Safety, patient demographics and service improvement metrics were included. The metrics will enable analysis of the effectiveness of allied health primary contact services and will facilitate reporting, advocacy, service improvement, service continuity and research. The metrics are suitable for use by all providers of allied health primary contact services in hospital and primary care settings.
- Published
- 2020
- Full Text
- View/download PDF
15. Implementation of simulation modelling to improve service planning in specialist orthopaedic and neurosurgical outpatient services.
- Author
-
Moretto N, Comans TA, Chang AT, O'Leary SP, Osborne S, Carter HE, Smith D, Cavanagh T, Blond D, and Raymer M
- Subjects
- Focus Groups, Health Services Needs and Demand, Humans, Qualitative Research, Queensland, Ambulatory Care standards, Delivery of Health Care standards, Implementation Science, Models, Organizational, Neurosurgery standards, Orthopedics standards, Outpatients, Planning Techniques, Quality Improvement
- Abstract
Background: Advanced physiotherapist-led services have been embedded in specialist orthopaedic and neurosurgical outpatient departments across Queensland, Australia, to ameliorate capacity constraints. Simulation modelling has been used to inform the optimal scale and professional mix of services required to match patient demand. The context and the value of simulation modelling in service planning remain unclear. We aimed to examine the adoption, context and costs of using simulation modelling recommendations to inform service planning., Methods: Using an implementation science approach, we undertook a prospective, qualitative evaluation to assess the use of discrete event simulation modelling recommendations for service re-design and to explore stakeholder perspectives about the role of simulation modelling in service planning. Five orthopaedic and neurosurgical services in Queensland, Australia, were selected to maximise variation in implementation effectiveness. We used the consolidated framework for implementation research (CFIR) to guide the facilitation and analysis of the stakeholder focus group discussions. We conducted a prospective costing analysis in each service to estimate the costs associated with using simulation modelling to inform service planning., Results: Four of the five services demonstrated adoption by inclusion of modelling recommendations into proposals for service re-design. Four CFIR constructs distinguished and two CFIR constructs did not distinguish between high versus mixed implementation effectiveness. We identified additional constructs that did not map onto CFIR. The mean cost of implementation was AU$34,553 per site (standard deviation = AU$737)., Conclusions: To our knowledge, this is the first time the context of implementing simulation modelling recommendations in a health care setting, using a validated framework, has been examined. Our findings may provide valuable insights to increase the uptake of healthcare modelling recommendations in service planning.
- Published
- 2019
- Full Text
- View/download PDF
16. The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
- Author
-
Gianello V, Salvi V, Parola C, Moretto N, Facchinetti F, Civelli M, Villetti G, Bosisio D, and Sozzani S
- Subjects
- Anti-Infective Agents pharmacology, Cells, Cultured, Cytokines genetics, Humans, T-Lymphocytes drug effects, T-Lymphocytes physiology, Cytokines metabolism, Dendritic Cells drug effects, Gene Expression Regulation drug effects, Phosphodiesterase 4 Inhibitors pharmacology, Sulfonamides pharmacology, para-Aminobenzoates pharmacology
- Abstract
Phosphodiesterase 4 (PDE4) inhibitors are used to treat autoimmune and inflammatory diseases, such as psoriasis and chronic obstructive pulmonary disease (COPD). CHF6001 is a novel, potent and selective inhaled PDE4 inhibitor in development for the treatment of COPD. When tested in vitro on human dendritic cells (DCs), CHF6001 decreased the release of pro-inflammatory cytokines (TNF-α and IL-6), chemokines (CXCL8, CCL3, CXCL10 and CCL19) and of Th1- and Th17-polarizing cytokines (IL-12, IL-23 and IL-1β). In contrast to β-methasone, a reference steroid anti-inflammatory drug, CHF6001 increased the secretion of CCL22, a Th2 recruiting chemokine, and the expression of the lymph node homing receptor CCR7. Accordingly, the migration of DCs to CCR7 ligands was increased, while migration to pro-inflammatory chemokines was decreased. Of note, the action of CHF6001 was apparently mediated by a promoter-specific decrease in NF-κB p65 recruitment, independent of perturbation of LPS signalling or NF-κB nuclear translocation. Our results indicate that CHF6001 can modulate DC pro-inflammatory Th1/Th17 polarizing potential by fine tuning the transcriptional activity of the master inflammatory transcription factor NF-κB. Therefore, CHF6001 may prove useful to control Th1/Th17-polarized inflammatory diseases such as COPD., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
17. Process to establish 11 primary contact allied health pathways in a public health service.
- Author
-
Stute M, Moretto N, Raymer M, Banks M, Buttrum P, Sam S, Bhagwat M, and Comans T
- Subjects
- Ambulatory Care Facilities, Health Services Needs and Demand, Hospitals, Public, Humans, Physicians, Queensland, Waiting Lists, Allied Health Personnel organization & administration, Appointments and Schedules, Delivery of Health Care methods, Referral and Consultation, Specialization
- Abstract
Objective Faced with longstanding and increasing demand for specialist out-patient appointments that was unable to be met through usual medical consultant led care, Metro North Hospital and Health Service in 2014-15 established 11 allied health primary contact out-patient models of care. Methods The models involved six different allied health professions and nine specialist out-patient departments. Results All the allied health models have been endorsed for continuation following demonstration of their contribution to managing demand on specialist out-patient services. Conclusion This paper describes key features of the allied health primary contact models of care and presents preliminary data including new case throughput, effect on wait times and enablers and challenges for clinic establishment. What is known about the topic? Allied health clinics have been demonstrated to result in high patient, referrer and consultant satisfaction, and are a cost-effective management strategy for wait list demand. In Queensland, physiotherapy-led orthopaedic clinics have been operating since 2005. What does this paper add? This paper describes the establishment of 11 allied health primary contact models of care in speciality out-patient areas including Ear, Nose and Throat, Gynaecology, Urology, Neurology, Neurosurgery, Orthopaedics and Plastic Surgery, and involving speech pathologists, audiologists, physiotherapists, occupational therapists and podiatrists as primary contact practitioners. Observations of enablers for and challenges to implementation are presented as key lessons. What are the implications for practitioners? The new allied health primary contact models of care described in this paper should be considered by health service executives, allied health leaders and specialist out-patient departments as one strategy to address unacceptably long specialist wait lists.
- Published
- 2018
- Full Text
- View/download PDF
18. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
- Author
-
Carzaniga L, Amari G, Rizzi A, Capaldi C, De Fanti R, Ghidini E, Villetti G, Carnini C, Moretto N, Facchinetti F, Caruso P, Marchini G, Battipaglia L, Patacchini R, Cenacchi V, Volta R, Amadei F, Pappani A, Capacchi S, Bagnacani V, Delcanale M, Puccini P, Catinella S, Civelli M, and Armani E
- Subjects
- Administration, Inhalation, Animals, Binding Sites, Cyclic Nucleotide Phosphodiesterases, Type 4 chemistry, Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism, Dose-Response Relationship, Drug, Drug Discovery, Drug Evaluation, Preclinical methods, Drug Stability, Humans, Male, Phosphodiesterase 4 Inhibitors administration & dosage, Pulmonary Eosinophilia drug therapy, Pyrrolidines chemistry, Rats, Inbred BN, Respiratory Tract Diseases drug therapy, Thiazoles chemistry, Phosphodiesterase 4 Inhibitors chemistry, Phosphodiesterase 4 Inhibitors pharmacology, Structure-Activity Relationship
- Abstract
Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein, we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent in vitro PDE4 inhibitors. (S*,S**)-18e and (S*,S**)-22e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid-state properties suggest that both compounds have the potential to be effective topical agents for treating respiratory inflammatory diseases.
- Published
- 2017
- Full Text
- View/download PDF
19. Public Preferences for the Use of Taxation and Labelling Policy Measures to Combat Obesity in Young Children in Australia.
- Author
-
Comans T, Moretto N, and Byrnes J
- Subjects
- Adult, Aged, Child, Cohort Studies, Female, Humans, Male, Middle Aged, Queensland, Food Labeling, Health Promotion methods, Nutrition Policy, Parents psychology, Pediatric Obesity prevention & control, Taxes
- Abstract
Objective : Childhood obesity is a serious concern for developed and developing countries. This study aimed to assess the level of support in Australia for regulation and to assess whether systematic differences occur between individuals who support increased regulation and individuals who oppose it. Methods : An online survey ( n = 563) was used to assess parental/caregiver preferences for taxation policy options and nutrition labelling designed to address the incidence of childhood obesity. Participants were parents or caregivers of young children (3 to 7 years) who were actively enrolled in an existing birth cohort study in South-East Queensland, Australia. Results : The majority of the parents (over 80%) strongly agreed or agreed with labelling food and drink with traffic light or teaspoon labelling. Support for taxation was more variable with around one third strongly supporting and a further 40% of participants equivocal about using taxation; however, a quarter strongly rejected this policy. Cluster analysis did not detect any socio-demographic differences between those who strongly supported taxation and those who did not. Conclusions : Better food labelling would be welcomed by parents to enhance food choices for their children. Taxation for health reasons would not be opposed by most parents. Implications for Public Health: Governments should consider taxation of unhealthy drinks and improved labelling to encourage healthy food purchasing.
- Published
- 2017
- Full Text
- View/download PDF
20. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
- Author
-
Moretto N, Caruso P, Bosco R, Marchini G, Pastore F, Armani E, Amari G, Rizzi A, Ghidini E, De Fanti R, Capaldi C, Carzaniga L, Hirsch E, Buccellati C, Sala A, Carnini C, Patacchini R, Delcanale M, Civelli M, Villetti G, and Facchinetti F
- Subjects
- Administration, Inhalation, Administration, Topical, Animals, Ferrets, Male, Mice, Inbred C57BL, Rats, Rats, Inbred BN, Rats, Sprague-Dawley, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents metabolism, Cyclic Nucleotide Phosphodiesterases, Type 4 metabolism, Phosphodiesterase 4 Inhibitors administration & dosage, Phosphodiesterase 4 Inhibitors metabolism
- Abstract
This study examined the pharmacologic characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration. CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, respectively, in inhibiting PDE4 enzymatic activity (IC50 = 0.026 ± 0.006 nM). CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site versus low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity versus PDE4 compared with a panel of PDEs. CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383). Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4(+) T cells. In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide]. When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.). In sum, CHF6001 has the potential to be an effective topical treatment of conditions associated with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease., (Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2015
- Full Text
- View/download PDF
21. Yes, the government should tax soft drinks: findings from a citizens' jury in Australia.
- Author
-
Moretto N, Kendall E, Whitty J, Byrnes J, Hills AP, Gordon L, Turkstra E, Scuffham P, and Comans T
- Subjects
- Adolescent, Adult, Aged, Australia, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Young Adult, Carbonated Beverages economics, Pediatric Obesity prevention & control, Public Opinion, Snacks, Taxes
- Abstract
Taxation has been suggested as a possible preventive strategy to address the serious public health concern of childhood obesity. Understanding the public's viewpoint on the potential role of taxation is vital to inform policy decisions if they are to be acceptable to the wider community. A Citizens' Jury is a deliberative method for engaging the public in decision making and can assist in setting policy agendas. A Citizens' Jury was conducted in Brisbane, Australia in May 2013 to answer the question: Is taxation on food and drinks an acceptable strategy to the public in order to reduce rates of childhood obesity? Citizens were randomly selected from the electoral roll and invited to participate. Thirteen members were purposively sampled from those expressing interest to broadly reflect the diversity of the Australian public. Over two days, participants were presented with evidence on the topic by experts, were able to question witnesses and deliberate on the evidence. The jurors unanimously supported taxation on sugar-sweetened drinks but generally did not support taxation on processed meats, snack foods and foods eaten/ purchased outside the home. They also supported taxation on snack foods on the condition that traffic light labelling was also introduced. Though they were not specifically asked to deliberate strategies outside of taxation, the jurors strongly recommended more nutritional information on all food packaging using the traffic light and teaspoon labelling systems for sugar, salt and fat content. The Citizens' Jury suggests that the general public may support taxation on sugar-sweetened drinks to reduce rates of obesity in children. Regulatory reforms of taxation on sugar-sweetened drinks and improved labelling of nutritional information on product packaging were strongly supported by all members of the jury. These reforms should be considered by governments to prevent childhood obesity and the future burden on society from the consequences of obesity.
- Published
- 2014
- Full Text
- View/download PDF
22. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
- Author
-
Armani E, Amari G, Rizzi A, De Fanti R, Ghidini E, Capaldi C, Carzaniga L, Caruso P, Guala M, Peretto I, La Porta E, Bolzoni PT, Facchinetti F, Carnini C, Moretto N, Patacchini R, Bassani F, Cenacchi V, Volta R, Amadei F, Capacchi S, Delcanale M, Puccini P, Catinella S, Civelli M, and Villetti G
- Subjects
- Administration, Inhalation, Animals, Anti-Inflammatory Agents, Non-Steroidal chemistry, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Benzoates chemistry, Benzoates pharmacology, Cell Line, Chronic Disease, Crystallography, X-Ray, Eosinophilia drug therapy, Eosinophilia immunology, Eosinophilia pathology, Esters, Guinea Pigs, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear enzymology, Lung drug effects, Lung immunology, Lung pathology, Molecular Docking Simulation, Ovalbumin, Phosphodiesterase 4 Inhibitors chemistry, Phosphodiesterase 4 Inhibitors pharmacology, Protein Conformation, Rats, Stereoisomerism, Structure-Activity Relationship, Sulfonamides chemistry, Sulfonamides pharmacology, para-Aminobenzoates chemistry, para-Aminobenzoates pharmacology, Anti-Inflammatory Agents, Non-Steroidal chemical synthesis, Asthma drug therapy, Benzoates chemical synthesis, Lung Diseases, Obstructive drug therapy, Phosphodiesterase 4 Inhibitors chemical synthesis, Sulfonamides chemical synthesis, para-Aminobenzoates chemical synthesis
- Abstract
The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described. A series of novel ester derivatives of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl) ethanol have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4). In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alcoholic and benzoic moieties were performed to maximize the inhibitory potency. Several compounds with high activity in cell-free and cell-based assays were obtained. Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.
- Published
- 2014
- Full Text
- View/download PDF
23. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells.
- Author
-
Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G, Patacchini R, Singh D, and Facchinetti F
- Subjects
- Bronchi pathology, Cells, Cultured, Chemotaxis drug effects, Dactinomycin pharmacology, Epithelial Cells pathology, Female, Humans, Male, Middle Aged, Myocytes, Smooth Muscle pathology, Neutrophil Activation drug effects, Neutrophils metabolism, Neutrophils pathology, Nucleic Acid Synthesis Inhibitors pharmacology, Pneumonia metabolism, Pneumonia pathology, Pulmonary Disease, Chronic Obstructive metabolism, Pulmonary Disease, Chronic Obstructive pathology, Respiratory Mucosa pathology, Acrolein toxicity, Bronchi metabolism, Epithelial Cells metabolism, Interleukin-8 biosynthesis, Intracellular Signaling Peptides and Proteins metabolism, MAP Kinase Signaling System drug effects, Myocytes, Smooth Muscle metabolism, Protein Serine-Threonine Kinases metabolism, RNA Stability drug effects, RNA, Messenger biosynthesis, Respiratory Mucosa metabolism, Tobacco Smoke Pollution adverse effects, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Interleukin-8 (IL-8/CXCL8) is an important neutrophil chemoattractant known to be elevated in the airways of cigarette smokers and in patients with chronic obstructive pulmonary disease (COPD). We examined the acute effect of aqueous cigarette smoke extract (CSE) on IL-8 expression in primary human pulmonary cells, in particular in normal human bronchial smooth muscle cells (HBSMCs). IL-8 mRNA levels increased upon CSE exposure in a concentration- and time-dependent manner, and such an effect was accompanied by IL-8 secretion. CSE-evoked elevation of IL-8 mRNA was mimicked by its component acrolein. Both CSE and acrolein induced p38 mitogen-activated protein kinase (MAPK) phosphorylation, accompanied by the phosphorylation of MAPK-activated kinase 2 (MK2), a known downstream substrate of the p38 MAPK, both in HBSMCs and in human airway epithelial cells. Furthermore, pharmacological inhibition of p38 MAPK or MK2 strongly accelerated the decay of IL-8 mRNA levels upon stimulation with CSE or acrolein and subsequent blockade of mRNA neosynthesis with actinomycin D in pulmonary structural cells (HBSMCs and airways epithelial cells) as well as in human alveolar macrophages. Conversely, pharmacological inhibition of ERK1/2 signaling inhibited CSE-induced steady-state levels of IL-8 mRNA without affecting mRNA stability, thus suggesting inhibition at the transcriptional level. In sum, p38 MAPK/MK2 signaling is an important posttranscriptional mechanism underlying upregulation of IL-8 mRNA levels elicited by CSE and acrolein. Given the pivotal role of IL-8 in neutrophil chemotaxis and activation, our results shed light on the mechanisms through which cigarette smoke can initiate inflammation in the lung.
- Published
- 2012
- Full Text
- View/download PDF
24. Acrolein effects in pulmonary cells: relevance to chronic obstructive pulmonary disease.
- Author
-
Moretto N, Volpi G, Pastore F, and Facchinetti F
- Subjects
- Acrolein toxicity, Air Pollutants pharmacology, Air Pollutants toxicity, Animals, Humans, Inflammation chemically induced, Inflammation complications, Lung cytology, Models, Biological, Pulmonary Disease, Chronic Obstructive immunology, Pulmonary Disease, Chronic Obstructive therapy, Tobacco Smoke Pollution adverse effects, Acrolein pharmacology, Lung drug effects, Pulmonary Disease, Chronic Obstructive etiology
- Abstract
Acrolein (2-propenal) is a highly reactive α,β-unsaturated aldehyde and a respiratory irritant that is ubiquitously present in the environment but that can also be generated endogenously at sites of inflammation. Acrolein is abundant in tobacco smoke, which is the major environmental risk factor for chronic obstructive pulmonary disease (COPD), and elevated levels of acrolein are found in the lung fluids of COPD patients. Its high electrophilicity makes acrolein notorious for its facile reaction with biological nucleophiles, leading to the modification of proteins and DNA and depletion of antioxidant defenses. As a consequence, acrolein results in oxidative stress as well as altered intracellular signaling and gene transcription/translation. In pulmonary cells, acrolein, at subtoxic concentrations, can activate intracellular stress kinases, alter the production of inflammatory mediators and proteases, modify innate immune response, induce mucus hypersecretion, and damage airway epithelium. A better comprehension of the mechanisms underlying acrolein effects in the airways may suggest novel treatment strategies in COPD., (© 2012 New York Academy of Sciences.)
- Published
- 2012
- Full Text
- View/download PDF
25. Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation.
- Author
-
Nassini R, Pedretti P, Moretto N, Fusi C, Carnini C, Facchinetti F, Viscomi AR, Pisano AR, Stokesberry S, Brunmark C, Svitacheva N, McGarvey L, Patacchini R, Damholt AB, Geppetti P, and Materazzi S
- Subjects
- Animals, Bronchoalveolar Lavage Fluid, Epithelial Cells metabolism, Fibroblasts metabolism, Humans, Immunohistochemistry methods, Inflammation, Interleukin-8 biosynthesis, Interleukin-8 metabolism, Mice, Mice, Transgenic, Muscle, Smooth metabolism, Smoking, TRPA1 Cation Channel, TRPV Cation Channels biosynthesis, Calcium Channels biosynthesis, Calcium Channels physiology, Gene Expression Regulation, Nerve Tissue Proteins biosynthesis, Nerve Tissue Proteins physiology, Respiratory System pathology, Transient Receptor Potential Channels biosynthesis, Transient Receptor Potential Channels physiology
- Abstract
Background: The transient receptor potential ankyrin 1 (TRPA1) channel, localized to airway sensory nerves, has been proposed to mediate airway inflammation evoked by allergen and cigarette smoke (CS) in rodents, via a neurogenic mechanism. However the limited clinical evidence for the role of neurogenic inflammation in asthma or chronic obstructive pulmonary disease raises an alternative possibility that airway inflammation is promoted by non-neuronal TRPA1., Methodology/principal Findings: By using Real-Time PCR and calcium imaging, we found that cultured human airway cells, including fibroblasts, epithelial and smooth muscle cells express functional TRPA1 channels. By using immunohistochemistry, TRPA1 staining was observed in airway epithelial and smooth muscle cells in sections taken from human airways and lung, and from airways and lung of wild-type, but not TRPA1-deficient mice. In cultured human airway epithelial and smooth muscle cells and fibroblasts, acrolein and CS extract evoked IL-8 release, a response selectively reduced by TRPA1 antagonists. Capsaicin, agonist of the transient receptor potential vanilloid 1 (TRPV1), a channel co-expressed with TRPA1 by airway sensory nerves, and acrolein or CS (TRPA1 agonists), or the neuropeptide substance P (SP), which is released from sensory nerve terminals by capsaicin, acrolein or CS), produced neurogenic inflammation in mouse airways. However, only acrolein and CS, but not capsaicin or SP, released the keratinocyte chemoattractant (CXCL-1/KC, IL-8 analogue) in bronchoalveolar lavage (BAL) fluid of wild-type mice. This effect of TRPA1 agonists was attenuated by TRPA1 antagonism or in TRPA1-deficient mice, but not by pharmacological ablation of sensory nerves., Conclusions: Our results demonstrate that, although either TRPV1 or TRPA1 activation causes airway neurogenic inflammation, solely TRPA1 activation orchestrates an additional inflammatory response which is not neurogenic. This finding suggests that non-neuronal TRPA1 in the airways is functional and potentially capable of contributing to inflammatory airway diseases.
- Published
- 2012
- Full Text
- View/download PDF
26. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation.
- Author
-
Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, Failli P, Preti D, Marchetti N, Cavazzini A, Mancini F, Pedretti P, Nilius B, Patacchini R, and Geppetti P
- Subjects
- Animals, Atropine pharmacology, Calcitonin Gene-Related Peptide metabolism, Calcium metabolism, Capsaicin analogs & derivatives, Capsaicin pharmacology, Cells, Cultured, Chromatography, High Pressure Liquid, Cisplatin pharmacology, Cricetinae, Cricetulus, Dipeptides pharmacology, Disease Models, Animal, Drug Interactions, Ganglia, Spinal cytology, Gene Expression Regulation drug effects, Gene Expression Regulation genetics, Guinea Pigs, Mice, Mice, Inbred C57BL, Mice, Knockout, Oxaliplatin, Pain Measurement, Piperazines, Pulmonary Artery drug effects, Quinazolines pharmacology, Rats, Rats, Sprague-Dawley, Reproducibility of Results, Sensory Receptor Cells drug effects, Spectrometry, Mass, Electrospray Ionization, Superoxides metabolism, TRPA1 Cation Channel, Tissue Culture Techniques, Transient Receptor Potential Channels antagonists & inhibitors, Transient Receptor Potential Channels deficiency, Antineoplastic Agents toxicity, Hyperalgesia chemically induced, Hyperalgesia metabolism, Organoplatinum Compounds toxicity, Transient Receptor Potential Channels metabolism
- Abstract
Platinum-based anticancer drugs cause neurotoxicity. In particular, oxaliplatin produces early-developing, painful, and cold-exacerbated paresthesias. However, the mechanism underlying these bothersome and dose-limiting adverse effects is unknown. We hypothesized that the transient receptor potential ankyrin 1 (TRPA1), a cation channel activated by oxidative stress and cold temperature, contributes to mechanical and cold hypersensitivity caused by oxaliplatin and cisplatin. Oxaliplatin and cisplatin evoked glutathione-sensitive relaxation, mediated by TRPA1 stimulation and the release of calcitonin gene-related peptide from sensory nerve terminals in isolated guinea pig pulmonary arteries. No calcium response was observed in cultured mouse dorsal root ganglion neurons or in naïve Chinese hamster ovary (CHO) cells exposed to oxaliplatin or cisplatin. However, oxaliplatin, and with lower potency, cisplatin, evoked a glutathione-sensitive calcium response in CHO cells expressing mouse TRPA1. One single administration of oxaliplatin produced mechanical and cold hyperalgesia in rats, an effect selectively abated by the TRPA1 antagonist HC-030031. Oxaliplatin administration caused mechanical and cold allodynia in mice. Both responses were absent in TRPA1-deficient mice. Administration of cisplatin evoked mechanical allodynia, an effect that was reduced in TRPA1-deficient mice. TRPA1 is therefore required for oxaliplatin-evoked mechanical and cold hypersensitivity, and contributes to cisplatin-evoked mechanical allodynia. Channel activation is most likely caused by glutathione-sensitive molecules, including reactive oxygen species and their byproducts, which are generated after tissue exposure to platinum-based drugs from cells surrounding nociceptive nerve terminals., (Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
27. Cigarette smoke and α,β-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts.
- Author
-
Volpi G, Facchinetti F, Moretto N, Civelli M, and Patacchini R
- Subjects
- Acetylcysteine pharmacology, Bronchi cytology, Bronchi drug effects, Bronchi metabolism, Calcium Channels, Cells, Cultured, Complex Mixtures pharmacology, Fibroblasts metabolism, Humans, Lung cytology, Lung metabolism, Myocytes, Smooth Muscle metabolism, Nerve Tissue Proteins antagonists & inhibitors, Nicotinic Antagonists pharmacology, Phosphorylation, RNA, Messenger metabolism, TRPA1 Cation Channel, Transient Receptor Potential Channels antagonists & inhibitors, Vascular Endothelial Growth Factor A genetics, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors, p38 Mitogen-Activated Protein Kinases metabolism, Acrolein pharmacology, Aldehydes pharmacology, Fibroblasts drug effects, Lung drug effects, Myocytes, Smooth Muscle drug effects, Smoke adverse effects, Nicotiana, Vascular Endothelial Growth Factor A metabolism
- Abstract
Background and Purpose: Vascular endothelial growth factor (VEGF) is an angiogenic factor known to be elevated in the sputum of asymptomatic smokers as well as smokers with bronchitis type of chronic obstructive pulmonary disease. The aim of this study was to investigate whether acute exposure to cigarette smoke extract altered VEGF production in lung parenchymal cells., Experimental Approach: We exposed human airway smooth muscle cells (ASMC), normal human lung fibroblasts (NHLF) and small airways epithelial cells (SAEC) to aqueous cigarette smoke extract (CSE) in order to investigate the effect of cigarette smoke on VEGF expression and release., Key Results: Vascular endothelial growth factor release was elevated by sub-toxic concentrations of CSE in both ASMC and NHLF, but not in SAEC. CSE-evoked VEGF release was mimicked by its component acrolein at concentrations (10-100 µM) found in CSE, and prevented by the antioxidant and α,β-unsaturated aldehyde scavenger, N-acetylcysteine (NAC). Both CSE and acrolein (30 µM) induced VEGF mRNA expression in ASMC cultures, suggesting an effect at transcriptional level. Crotonaldehyde and 4-hydroxy-2-nonenal, an endogenous α,β-unsaturated aldehyde, stimulated VEGF release, as did H(2)O(2). CSE-evoked VEGF release was accompanied by rapid and lasting phosphorylation of p38 MAPK (mitogen-activated protein kinase), which was abolished by NAC and mimicked by acrolein. Both CSE- and acrolein-evoked VEGF release were blocked by selective inhibition of p38 MAPK signalling., Conclusions and Implications: α,β-Unsaturated aldehydes and possibly reactive oxygen species contained in cigarette smoke stimulate VEGF expression and release from pulmonary cells through p38 MAPK signalling., (© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.)
- Published
- 2011
- Full Text
- View/download PDF
28. alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases.
- Author
-
Moretto N, Facchinetti F, Southworth T, Civelli M, Singh D, and Patacchini R
- Subjects
- Acetylcysteine pharmacology, Aged, Cell Survival drug effects, Epithelial Cells cytology, Epithelial Cells drug effects, Extracellular Signal-Regulated MAP Kinases metabolism, Female, Fibroblasts cytology, Fibroblasts drug effects, Fibroblasts enzymology, Humans, Macrophages cytology, Macrophages drug effects, Macrophages metabolism, Male, Mesna pharmacology, Middle Aged, NF-kappa B metabolism, Reactive Oxygen Species metabolism, p38 Mitogen-Activated Protein Kinases metabolism, Aldehydes pharmacology, Epithelial Cells metabolism, Fibroblasts metabolism, Interleukin-8 metabolism, Lung cytology, Mitogen-Activated Protein Kinases metabolism, Smoking
- Abstract
Cigarette smoking is the major risk factor for chronic obstructive pulmonary disease (COPD), a syndrome characterized by pulmonary neutrophil infiltration, chronic inflammation, and progressive tissue destruction. We examined here the acute effect of aqueous cigarette smoke extract (CSE) and of two alpha,beta-unsaturated aldehydes (acrolein and crotonaldehyde) contained in CSE in cultured normal human lung fibroblasts and small airway epithelial cells. By examining a panel of 19 cytokines and chemokines, we found that IL-8 release was elevated by CSE as well as by acrolein, whereas other inflammatory mediators were mostly unaffected. CSE-evoked IL-8 release was mimicked by acrolein and crotonaldehyde at concentrations (3-60 microM each) found in CSE and fully prevented by 1 mM alpha,beta-unsaturated aldehydes scavengers N-acetylcysteine (NAC) or sodium 2-mercaptoethanesulfonate. Neither the saturated aldehyde acetaldehyde nor H(2)O(2) evoked IL-8 release. In addition, CSE or crotonaldehyde upregulated the release of IL-8 from alveolar macrophages from both COPD patients and healthy nonsmokers, indicating that this is a response common to cells involved in lung inflammation. CSE-evoked IL-8 release was accompanied by increased phosphorylation of p38 MAPK and ERK1/2. CSE-evoked p38 and ERK1/2 phosphorylation was mimicked by acrolein and inhibited by NAC. IL-8 release elicited by both acrolein and CSE was blocked by pharmacological inhibition of p38 and ERK1/2 phosphorylation. In summary, our data show that alpha,beta-unsaturated aldehydes-evoked phosphorylation of p38 and ERK1/2 underlies IL-8 release elicited by CSE, thus shedding light on the mechanisms through which cigarette smoke can initiate inflammation in the lung.
- Published
- 2009
- Full Text
- View/download PDF
29. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
- Author
-
Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, and Ottonello S
- Subjects
- Animals, Antibodies, Viral immunology, Cell Line, Female, Human papillomavirus 16 immunology, Immune Sera immunology, Mice, Mice, Inbred BALB C, Neutralization Tests, Papillomavirus Infections immunology, Recombinant Fusion Proteins immunology, Tandem Repeat Sequences, Thioredoxins immunology, Antigens, Viral immunology, Capsid Proteins immunology, Oncogene Proteins, Viral immunology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines immunology
- Abstract
The minor capsid protein L2 is a promising candidate for the construction of an anti-human papillomavirus (HPV) broadly protective vaccine for the prophylaxis of cervical cancer. However, L2-derived peptides are usually poorly immunogenic and extensive knowledge on the most relevant (cross)neutralizing epitope(s) is still needed. We systematically examined the immunogenicity and virus neutralization potential of six peptides encompassing the N-terminal (amino acids 1 -- 120) region of HPV16 L2 (20 -- 38; 28 -- 42; 56 -- 75; 64 -- 81; 96 -- 115; 108 -- 120) using bacterial thioredoxin (Trx) as a novel peptide scaffold. Mice antisera generated by 19 different Trx-L2 peptide fusions bearing one or multiple copies of each peptide were analyzed. Internal fusion to thioredoxin conferred strong immunogenicity to all the tested peptides, with a trend toward an increased immunogenicity for the multipeptide vs. the monopeptide forms of the various antigens. All Trx-L2 peptides induced HPV16 neutralizing antibodies in some of the immunized mice, but neutralization titers differed by more than two orders of magnitude. Trx-L2(20 -- 38) antisera were by far the most effective in HPV16 neutralization and did not differ significantly from those induced by a reference polypeptide covering the entire L2 (1 -- 120) region. The same antisera were also the most effective when challenged against the non-cognate HPV 18, 58, 45 and 31 pseudovirions. The data identify L2(20 -- 38) as the best (cross)neutralizing epitope among the six that were examined, and point to thioredoxin fusion derivatives of this peptide as excellent candidates for the formulation of a low-cost, broadly protective HPV vaccine.
- Published
- 2009
- Full Text
- View/download PDF
30. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
- Author
-
Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, and Ottonello S
- Subjects
- Alzheimer Disease metabolism, Alzheimer Disease pathology, Amyloid beta-Peptides chemistry, Amyloid beta-Peptides metabolism, Animals, Brain metabolism, Brain pathology, Humans, Male, Mice, Mice, Inbred BALB C, Mice, Transgenic, Models, Molecular, Protein Structure, Tertiary, Recombinant Proteins chemistry, Recombinant Proteins immunology, Recombinant Proteins metabolism, Thioredoxins chemistry, Thioredoxins metabolism, Alzheimer Disease immunology, Amyloid beta-Peptides immunology, Antibodies immunology, Epitopes, B-Lymphocyte immunology, Peptide Fragments immunology, Thioredoxins immunology
- Abstract
Immunotherapy against the amyloid-beta (Abeta) peptide is a valuable potential treatment for Alzheimer disease (AD). An ideal antigen should be soluble and nontoxic, avoid the C-terminally located T-cell epitope of Abeta, and yet be capable of eliciting antibodies that recognize Abeta fibrils and neurotoxic Abeta oligomers but not the physiological monomeric species of Abeta. We have described here the construction and immunological characterization of a recombinant antigen with these features obtained by tandem multimerization of the immunodominant B-cell epitope peptide Abeta1-15 (Abeta15) within the active site loop of bacterial thioredoxin (Trx). Chimeric Trx(Abeta15)n polypeptides bearing one, four, or eight copies of Abeta15 were constructed and injected into mice in combination with alum, an adjuvant approved for human use. All three polypeptides were found to be immunogenic, yet eliciting antibodies with distinct recognition specificities. The anti-Trx(Abeta15)4 antibody, in particular, recognized Abeta42 fibrils and oligomers but not monomers and exhibited the same kind of conformational selectivity against transthyretin, an amyloidogenic protein unrelated in sequence to Abeta. We have also demonstrated that anti-Trx(Abeta15)4, which binds to human AD plaques, markedly reduces Abeta pathology in transgenic AD mice. The data indicate that a conformational epitope shared by oligomers and fibrils can be mimicked by a thioredoxin-constrained Abeta fragment repeat and identify Trx(Abeta15)4 as a promising new tool for AD immunotherapy.
- Published
- 2007
- Full Text
- View/download PDF
31. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
- Author
-
Imbimbo BP, Del Giudice E, Cenacchi V, Volta R, Villetti G, Facchinetti F, Riccardi B, Puccini P, Moretto N, Grassi F, Ottonello S, and Leon A
- Subjects
- Administration, Oral, Amyloid beta-Protein Precursor genetics, Animals, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics, Brain metabolism, Brain pathology, Cell Line, Tumor, Cell Survival drug effects, Cyclooxygenase 1 drug effects, Cyclooxygenase 1 genetics, Cyclooxygenase 1 metabolism, Cyclooxygenase 2 drug effects, Cyclooxygenase 2 genetics, Cyclooxygenase 2 metabolism, Cyclooxygenase Inhibitors pharmacology, Cyclopropanes administration & dosage, Cyclopropanes pharmacokinetics, Dose-Response Relationship, Drug, Down-Regulation, Flurbiprofen administration & dosage, Flurbiprofen pharmacokinetics, Gene Expression drug effects, Humans, Insecta cytology, Membrane Proteins drug effects, Membrane Proteins genetics, Membrane Proteins metabolism, Mice, Mice, Transgenic, Mutation, Nootropic Agents administration & dosage, Nootropic Agents pharmacokinetics, Time Factors, Transfection, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor metabolism, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Brain drug effects, Cyclopropanes pharmacology, Flurbiprofen analogs & derivatives, Flurbiprofen pharmacology, Nootropic Agents pharmacology, Peptide Fragments metabolism
- Abstract
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) may delay or prevent the onset of Alzheimer's disease (AD). A subset of NSAIDs, including flurbiprofen, has been shown to selectively inhibit the production of beta-amyloid(1-42) (Abeta42), independently from their cyclooxygenase (COX) inhibiting activity. We evaluated the in vitro and in vivo profiles of CHF5022 and CHF5074, two flurbiprofen analogues. The in vitro Abeta inhibiting activity was evaluated in a human neuroglioma cell line (H4) carrying the double Swedish mutation (K595N/M596L) of the human amyloid precursor protein (APPsw). The in vitro anti-COX activity was evaluated using human recombinant enzymes isolated from transfected Sf-9 cells. The in vivo pharmacokinetic and pharmacodynamic profiles of the two compounds were evaluated in young APPsw transgenic mice (Tg2576) after oral gavage (100 or 300mgkg(-1) day(-1) for 4-5 days) and after medicated diet (375ppm for 4 weeks). R-Flurbiprofen was used as comparator. In vitro, CHF5022 and CHF5074 were found to be 3- and 7-fold more potent than R-flurbiprofen in inhibiting Abeta42 secretion (IC(50)s of 92, 40 and 268microM, respectively). Differently from R-flurbiprofen, CHF5022 and CHF5074 did not affect COX-1 (at 100microM) and COX-2 (at 300microM) activity. Similarly to R-flurbiprofen, no significant alteration in the expression profile of a subset of Notch intracellular domain-responsive genes was observed with either CHF5022 or CHF5074. In Tg2576 mice, CHF5022 was well tolerated when administered by oral gavage (100mgkg(-1) day(-1) for 5 days) or by medicated diet (56mg kg(-1) day(-1) for 4 weeks). R-Flurbiprofen was poorly tolerated in the diet (32mgkg(-1) day(-1)) with 55% of the animals dying during the first week of treatment. After 4-5 days of oral gavage, CHF5022 and CHF5074 plasma and brain levels at 3h were found to increase with the dose, leading to brain concentrations of about 10% and 5% of the corresponding plasma concentrations, respectively. In animals fed for 4 weeks with compound-supplemented diet, mean plasma (580microM) and brain (20microM) Cyrillic) concentrations of CHF5022 were 8 and 15 times higher than those of R-flurbiprofen. Plasma Abeta42 concentration was dose-dependently decreased by CHF5022 and CHF5074. Brain Abeta levels (formic acid-extractable) were not significantly affected by either compound, although Abeta42 levels tended to inversely correlate (P=0.105) with CHF5022 concentration in the brain. CHF5022 and CHF5074 thus appear to have a promising in vitro and in vivo profile. This warrants further evaluation of their long-term effects on Abeta brain pathology.
- Published
- 2007
- Full Text
- View/download PDF
32. Structural and functional properties of lengsin, a pseudo-glutamine synthetase in the transparent human lens.
- Author
-
Grassi F, Moretto N, Rivetti C, Cellai S, Betti M, Márquez AJ, Maraini G, and Ottonello S
- Subjects
- Alternative Splicing, Amyloid beta-Peptides metabolism, Anilino Naphthalenesulfonates chemistry, Cataract metabolism, Cross Reactions, Eye Proteins chemistry, Eye Proteins genetics, Fluorescent Dyes, Glutamate-Ammonia Ligase chemistry, Glutamate-Ammonia Ligase genetics, Glutamate-Ammonia Ligase immunology, Humans, Peptide Fragments metabolism, Phylogeny, Eye Proteins physiology, Glutamate-Ammonia Ligase physiology, Lens, Crystalline metabolism
- Abstract
Lengsin (LGS) is an abundant transcript in the human lens, encoding a predicted polypeptide similar to glutamine synthetase (GS). We show that a major alternatively spliced product of LGS codes for a 57kDa polypeptide that assembles into a catalytically inactive dodecamer, cross-reacts with anti-GS antibodies, and is expressed at high levels in transparent, but not cataractous, human lenses. Based on this characteristic oligomeric organization, preferential expression in the transparent lens, and amyloid-beta association previously reported for GS, a potential chaperone-like role of LGS has been investigated. We find that LGS has six binding sites for the hydrophobic surface probe bis-ANS and relieves cellular toxicity caused by amyloid-beta expression in a folding-impaired yeast mutant. While documenting the structural similarity between LGS and prokaryotic GS-I, the data rule out any involvement of lengsin in glutamine biosynthesis and suggest an unrelated role that may be important for lens homeostasis and transparency.
- Published
- 2006
- Full Text
- View/download PDF
33. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
- Author
-
Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, Fontanella L, Misiano P, Bigogno C, Rizzi A, Riccardi B, Biscaioli M, Marchetti S, Puccini P, Catinella S, Rondelli I, Cenacchi V, Bolzoni PT, Caruso P, Villetti G, Facchinetti F, Del Giudice E, Moretto N, and Imbimbo BP
- Subjects
- Administration, Oral, Alzheimer Disease blood, Alzheimer Disease genetics, Amyloid beta-Peptides blood, Amyloid beta-Peptides metabolism, Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Blood-Brain Barrier metabolism, Caco-2 Cells, Cell Line, Tumor, Cell Membrane Permeability, Cyclooxygenase Inhibitors pharmacology, Flurbiprofen pharmacology, Glioma, Humans, Immunoassay, In Vitro Techniques, Injections, Intravenous, Mice, Mice, Transgenic, Peptide Fragments blood, Peptide Fragments metabolism, Rats, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Stereoisomerism, Structure-Activity Relationship, Amyloid beta-Peptides antagonists & inhibitors, Anti-Inflammatory Agents, Non-Steroidal chemical synthesis, Flurbiprofen analogs & derivatives, Flurbiprofen chemical synthesis, Peptide Fragments antagonists & inhibitors
- Abstract
Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit beta-amyloid(1)(-)(42) (Abeta42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing Abeta42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on Abeta42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Abeta42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.
- Published
- 2005
- Full Text
- View/download PDF
34. A high-affinity ammonium transporter from the mycorrhizal ascomycete Tuber borchii.
- Author
-
Montanini B, Moretto N, Soragni E, Percudani R, and Ottonello S
- Subjects
- Amino Acid Sequence, Ascomycota genetics, Base Sequence, Carrier Proteins genetics, Carrier Proteins isolation & purification, DNA, Complementary genetics, DNA, Complementary isolation & purification, DNA, Fungal genetics, DNA, Fungal isolation & purification, Fungal Proteins genetics, Fungal Proteins isolation & purification, Genes, Fungal, Genetic Complementation Test, Kinetics, Models, Molecular, Molecular Sequence Data, Phylogeny, Protein Structure, Secondary, RNA, Fungal genetics, RNA, Fungal metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Ascomycota metabolism, Carrier Proteins metabolism, Cation Transport Proteins, Fungal Proteins metabolism, Plant Proteins, Quaternary Ammonium Compounds metabolism
- Abstract
An ammonium transporter cDNA, named TbAMT1, was isolated from the ectomycorrhizal ascomycetous truffle Tuber borchii. The polypeptide encoded by TbAMT1 (52 kDa) functionally complements ammonium uptake-defective yeast mutants and shares sequence similarity with previously characterized ammonium transporters from Saccharomyces (Mep) and Arabidopsis (AtAMT1). Structural characteristics common to the Mep/Amt family and peculiar features of the Tuber transporter have been evidenced by a detailed topological model of the TbAMT1 protein, which predicts 11 transmembrane helices with an N terminus(OUT)/C terminus(IN) orientation. As revealed by uptake/competition experiments conducted in yeast, TbAMT1 is a high-affinity transporter with an apparent K(m) for ammonium of 2 microM. The TbAMT1 mRNA was very slowly, yet specifically upregulated in nitrogen-deprived T. borchii mycelia. Instead, a much faster return to basal expression levels was observed upon resupplementation of either ammonium or nitrate, which thus appear to be utilized as equally effective nitrogen sources by Tuber mycelia.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.